Hypertension is a side effect of systemically administered glucocorticoids, but the underlying molecular mechanism remains poorly understood. Ingestion of dexamethasone by rats telemetrically instrumented increased blood pressure progressively over 7 days. Plasma concentrations of Na ؉ and K ؉ and urinary Na ؉ and K ؉ excretion remained constant, excluding a mineralocorticoid-mediated mechanism. Plasma NO 2 ؊ ͞NO3 ؊ (the oxidation products of NO) decreased to 40%, and the expression of endothelial NO synthase (NOS III) was found down-regulated in the aorta and several other tissues of glucocorticoid-treated rats. The vasodilator response of resistance arterioles was tested by intravital microscopy in the mouse dorsal skinfold chamber model. Dexamethasone treatment significantly attenuated the relaxation to the endothelium-dependent vasodilator acetylcholine, but not to the endothelium-independent vasodilator S-nitroso-N-acetyl-D,L-penicillamine. Incubation of human umbilical vein endothelial cells, EA.hy 926 cells, or bovine aortic endothelial cells with several glucocorticoids reduced NOS III mRNA and protein expression to 60 -70% of control, an effect that was prevented by the glucocorticoid receptor antagonist mifepristone. Glucocorticoids decreased NOS III mRNA stability and reduced the activity of the human NOS III promoter (3.5 kilobases) to Ϸ70% by decreasing the binding activity of the essential transcription factor GATA. The expressional down-regulation of endothelial NOS III may contribute to the hypertension caused by glucocorticoids.
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dexamethasone ͉ dihydrocortisol ͉ RNase protection assay ͉ Western blot ͉ Reporter gene assay ͉ E ndothelium-derived NO is a physiologically significant vasodilator. Pharmacological inhibition of the endothelial NO synthase (NOS III) increases blood pressure (1) , and mice lacking the NOS III gene are hypertensive (2) . Endothelial NO is also an inhibitor of platelet aggregation and adhesion (3, 4) and can prevent leukocyte adhesion to the endothelium by down-regulating the leukocyte adhesion glycoprotein complex CD11͞CD18 (5) . Finally, NO also has been shown to inhibit DNA synthesis, mitogenesis, and proliferation of vascular smooth muscle cells (6, 7) . Therefore, endothelial NO is likely to represent a protective antiatherogenic principle (8) , and up-or down-regulation of NOS III could have important consequences for vascular homeostasis (9) .
Hypertension with diverse sequelae such as increased atherosclerosis, stroke, cerebral hemorrhage, and hypertensive cardiomyopathy is the major cardiovascular side effect of systemically administered glucocorticoids (10, 11) . The mechanism underlying this hypertension remains poorly understood (11) . Although cortisol-induced hypertension is characterized by Na ϩ retention and volume expansion, studies with synthetic glucocorticoids such as dexamethasone suggest that the hypertension is, to a substantial degree, independent of mineralocorticoid effects (11) . There is evidence for the presence of glucocorticoid receptors on endothelial cells (12) and vascular smooth muscle cells (13) . Therefore, actions of glucocorticoids on the vasculature are conceivable. Indeed, effects of glucocorticoids on vascular resistance have been demonstrated and have been explained in part by an increased response of the vasculature to catecholamines and angiotensin II (10, 11) .
We now demonstrate in vitro and ex vivo that glucocorticoids down-regulate endothelial NOS III expression by decreasing the stability of NOS III mRNA and reducing NOS III gene transcription. The resulting reduction in endothelial NO production could contribute to the increase in blood pressure seen with glucocorticoid therapy.
Methods
Reagents. Actinomycin D, dexamethasone, N G -nitro-L-arginine methylester (L-NAME) and S-nitroso-N-acetyl-D,L-penicillamine (SNAP), goat anti-rabbit antibody conjugated to alkaline phosphatase, horse anti-mouse antibody conjugated to alkaline phosphatase, and mouse monoclonal antibody to ␤-tubulin were obtained from Sigma. DMEM and Ham's F-12 nutrient mixture were from Life Technologies (Paisley, Scotland). Restriction enzymes, random hexamer primers, SureClone Ligation Kit, Taq DNA polymerase, Taq polymerase reaction buffer and T7 Sequencing Kit were from Amersham Pharmacia. Custom oligonucleotides were from MWG Biotech (Heidelberg, Germany). 3-Isobutyl-1-methylxanthine and superoxide dismutase were from Boehringer Ingelheim. pCR-Script and NucTrap probe purification columns were from Stratagene. DNase I, RNase A, RNase T1, proteinase K, T3͞T7 RNA polymerase, and nitrate reductase were from Roche Diagnostics. Luciferase assay system with reporter lysis buffer was from Promega.
[␣-32 P]UTP was from ICN. Mifepristone (RU 38486) was a generous gift of Roussel-UCLAF. Rabbit polyclonal antibody to NOS III was from Transduction Laboratories (Lexington, KY).
Telemetric Measurement of Blood Pressure and Heart Rate in Rats.
Male Wistar-Kyoto rats (from Charles River Breeding Laboratories, Sulzfeld, Germany) were housed singly under controlled environmental conditions (23 Ϯ 1°C, light:dark, 12:12 h, light on at 7:00 a.m.). Food (regular rat chow) and water were always available. Food and water intake were measured continuously Abbreviations: L-NAME, N G -nitro-L-arginine methylester; NOS III, endothelial-type nitric oxide synthase; SNAP, S-nitroso-N-acetyl-D,L-penicillamine; PLSD test, protected leastsignificant-difference test.
with a PC-controlled monitoring system (Feeding͞Drinking Monitor, Technical & Scientific Equipment, Bad Homburg, Germany). This device records hydrostatic pressure in the water bottle and the weight of the food container. Systolic and diastolic blood pressures were measured telemetrically in freely moving animals by using implanted transmitters as described (14) . Monitoring of cardiovascular parameters started 1 week after implantation of the pressure transmitters. Measurements were taken every 5 min by using the DataQuest System (Datasciences, St. Paul) and were averaged over 24 h by using DQ-FIT software (15) . Based on the average water intake of the rats (Ϸ100 ml͞kg of body weight͞day; determined before the experiment), dexamethasone was added to the drinking water at a concentration of 3 mg͞liter to reach a target dose of 0.3 mg͞kg͞day, and L-NAME was added at 100 mg͞liter to reach a target dose of 10 mg͞kg͞day. (18), and bovine aortic endothelial cells (19) were grown in DMEM with 10% fetal bovine serum, 2 mM L-glutamine, penicillin, and streptomycin. The three cell types were incubated for 18-36 h with dexamethasone (10 nM to 1 M), dihydrocortisol (100 nM to 10 M), or beclomethasone (10 nM to 1 M), or were left untreated (control). Then, RNA or protein was extracted or the NOS activity of the intact cells determined (see below). In experiments with the glucocorticoid receptor antagonist mifepristone (1 to 10 M), the antagonist was added 30 min before dexamethasone.
RNase Protection Assay of NOS III mRNA. Total RNA was isolated from the human or bovine endothelial cells and from several rat tissues by guanidinium thiocyanate͞phenol͞chloroform extraction (20) . Radiolabeled antisense RNA probes for human NOS III and human ␤-actin were prepared by in vitro transcription of the cDNA clones pCR-NOS III-Hu (21) and pCR-␤-actin-Hu (22) as described (21, 23) . Bovine and rat cDNAs were generated by reverse transcription of mRNA from bovine aortic endothelial cells and rat aorta, respectively. Bovine or rat NOS III cDNA fragments were amplified by PCR using the same oligonucleotide primers: 5Ј-GACATTGAGAGCAAAGGG-CTGC-3Ј (sense) and 5Ј-CGGCTTGTCACCTCCTGG-3Ј (antisense). Bovine ␤-actin and rat ␥-actin cDNA fragments were amplified by PCR using the following oligonucleotide primers: 5Ј-ACCAACTGGGACGACATGGAG-3Ј (sense) and 5Ј-CGTGAGGATCTTCATGAGGTAGTC-3Ј (antisense) (24) . The cDNA fragments (NOS III, 425 bp; ␥-actin, 353 bp) were cloned into the EcoRV site of vector pCR-Script (generating the cDNA clones pCR-NOS III-rat and pCR-␥-actin-rat) and sequenced ( T7 Sequencing Kit). A portion (0.5 g) of each DNA was in vitro transcribed by using T7͞T3 RNA polymerase and [␣-32 P]UTP. The template DNA was degraded with DNase I, and the radiolabeled RNA was purified by using NucTrap probe purification columns. RNase protection assays were performed as described (21, 23 ) with a mixture of RNase A and RNase T1. Densitometric analyses of the RNase protection gels were performed by using a Phospho-Imager (Bio-Rad). The density of each NOS III band was normalized with the corresponding ␤-actin or ␥-actin band.
NOS III Protein Preparation and Western
Blotting. Protein isolation and Western blotting were done as described (21, 25) . In brief, a CH A PS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) extract was prepared from the different types of endothelial cells and was separated by sodium dodecylsulfate polyacrylamide gel electrophoresis (7.5% gels). The proteins were transferred to nitrocellulose membranes (Schleicher & Schüll) by electroblotting (Bio-Rad). Proteins were detected by using a polyclonal anti-NOS III antibody (1:500) and a monoclonal anti-␤-tubulin antibody (1:500). After an incubation with the appropriate secondary antibodies conjugated to alkaline phosphatase as described (25), densitometric analyses were performed with a Video-Imager (Bio-Rad). NOS III protein bands were normalized by using the respective ␤-tubulin protein bands (21) .
Determination of NOS III Activity. NOS III activity was bioassayed by using the stimulation of soluble guanylyl cyclase in RFL-6 rat lung fibroblasts as described (26) . Dexamethasone-pretreated endothelial cells or control cells were incubated for 2 min at 37°C in 1 ml of Locke's solution containing 0.3 mM 3-isobutyl-1-methylxanthine and 20 units͞ml superoxide dismutase. Then, the conditioned media were transferred to the RFL-6 cells. After a 2-min incubation at 37°C on the RFL-6 cells, the reaction was stopped with 1 ml of ice-cold 50 mM sodium acetate buffer (pH 4.0) and by rapidly freezing the cells with liquid nitrogen. The cGMP content of the RFL-6 samples was determined by radioimmunoassay as described (26) .
Reporter Gene Assay Using the 5-Flanking Region of the Human
NOS III Gene Stably Transfected into EA.hy 926 Cells. EA.hy 926 cells stably transfected with the plasmid pNOS III-Hu-3500-Luc-neo have been described (23) . This plasmid contains 3.5 kilobases of the human NOS III promoter sequence (position Ϫ3,470 to ϩ115) cloned before the luciferase reporter gene (23) . Extracts of dexamethasone-treated cells and normal control cells were prepared by using the reporter lysis buffer, and luciferase activity was determined by using the luciferase assay system as described (21, 23) .
Electrophoretic Mobility Shift Assays. Binding activities of transcription factors Sp1 and GATA in nuclear extracts from dexamethasone-treated or untreated cells were determined by electrophoretic mobility shift assays as described (21) . Ten micrograms of nuclear protein were incubated with 17.5 fmol 32 Plabeled double-stranded oligonucleotide containing a consensus Sp1-binding motif (5Ј-ATTCGATCGGGGCGGGGCGAGC-3Ј, Promega), the Sp1 element (positions Ϫ109 to Ϫ91) of the human NOS III promoter (5Ј-GGATAGGGGCGGGGC-GAGG-3Ј) (27) , a consensus GATA-binding motif (5Ј-CACTTGATAACAGAAAGTGATAACTCT-3Ј, Santa Cruz Biotechnology), or the GATA site (positions Ϫ239 to Ϫ218) of the human NOS III promoter (5Ј-GCTCCCACTTATCAGC-CTCAGT-3Ј) (27) . Specificity of binding was determined by adding excess (1.75 pmol) unlabeled oligonucleotide. Gels were autoradiographed on x-ray film.
Statistics. Data represent means Ϯ SEM. Statistical differences were determined by Wilcoxon signed rank test or by factorial analysis of variance followed by Fisher's protected leastsignificant-difference (PLSD) test for comparison of multiple means.
Results

Ingestion of Dexamethasone Increased Blood Pressure and Decreased Serum NO 2
؊ ͞NO3 ؊ in Rats. Untreated rats were normotensive with 24-h average blood pressures of 121.3 Ϯ 1.1͞88.1 Ϯ 0.9 mmHg (systolic͞diastolic). When the dexamethasone treatment was started, the water intake of the rats decreased initially; the target dose of 0.3 mg͞kg͞day was reached after Ϸ5 days (Fig. 1) . Dexamethasone treatment resulted in an increase in blood pressure that reached a plateau after 1 week of treatment (Fig. 1) . When dexamethasone treatment was discontinued [by tapering off the daily dose over 3 days (Fig. 1) ], blood pressure returned to normal levels (Fig. 1) . Na ϩ and K ϩ concentrations in rat plasma were 148 Ϯ 3.8 mM and 6.6 Ϯ 0.43 mM, respectively (n ϭ 6). They remained unchanged after dexamethasone (145 Ϯ 4.4 and 7.35 Ϯ 0.39 mM, respectively). Control 24-h excretion of Na ϩ and K ϩ was 0.75 Ϯ 0.07 and 1.39 Ϯ 0.10 mmol͞day, respectively (n ϭ 6). After dexamethasone treatment, it was 0.82 Ϯ 0.06 and 1.18 Ϯ 0.13 mmol͞day, respectively. However, a 15-day administration of dexamethasone (Ϸ0.3 mg͞kg͞day) significantly reduced serum NO 2 Ϫ ͞NO 3 Ϫ levels from 17.4 Ϯ 1.7 to 6.9 Ϯ 0.7 M (n ϭ 5, P Ͻ 0.001). NO 2 Ϫ ͞NO 3 Ϫ levels returned to normal (17.1 Ϯ 1.4 M) after 7 days of cessation of dexamethasone treatment. A moderate dose (10 mg͞kg͞day) of the NOS inhibitor L-NAME, given for 7 days, produced a very similar increase in blood pressure as dexamethasone (from 125.2 Ϯ 0.9͞87.6 Ϯ 0.6 mmHg, systolic͞diastolic, to 144.2 Ϯ 0.9͞98.1 Ϯ 0.8 mmHg). Interestingly, the reduction in plasma NO 2 Ϫ ͞NO 3 Ϫ produced by this dose of L-NAME was virtually the same as that produced by dexamethasone (NO 2 Ϫ ͞NO 3 Ϫ levels decreased from 17.4 Ϯ 1.7 to 9.5 Ϯ 1.6 M; n ϭ 5, P Ͻ 0.001).
Dexamethasone Treatment Decreased NOS III mRNA Levels in the Aorta and Other Tissues. When rats were treated with dexamethasone (0.3 mg͞kg͞day) as described above and killed on days 3, 6, and 9 of treatment, NOS III mRNA levels in the aorta were found to be reduced by up to 40% (Fig. 2) . The dexamethasone treatment also reduced NOS III mRNA levels in the liver and the kidney (Fig. 2) but not in the heart (n ϭ 5, data not shown).
Dexamethasone Treatment Selectively Attenuated Endothelium-Dependent Vasodilatation in Resistance Arterioles. Dexamethasone treatment (Ϸ0.3 mg͞kg͞day) of C57͞BL 6J mice significantly attenuated the vasorelaxation in response to the endotheliumdependent vasodilator acetylcholine (10 M; Fig. 3 ). The same dexamethasone treatment had no significant effect on the vasorelaxation of resistance arterioles to superfusion with 10 M SNAP (Fig. 3) .
Glucocorticoids Decreased NOS III mRNA Levels in Three Types of
Endothelial Cells. When EA.hy 926 cells, human umbilical vein endothelial cells, or bovine aortic endothelial cells were treated with dexamethasone (10 nM to 1 M for 18 h), NOS III mRNA decreased to 60-70% of control (Fig. 4) . Also, beclomethasone (10 nM to 1 M) and dihydrocortisol (0.1 to 100 M) reduced NOS III mRNA expression in EA.hy 926 cells to a similar extent (n ϭ 3 each, data not shown). The inhibition of NOS III mRNA expression by dexamethasone was prevented by the glucocorticoid receptor antagonist mifepristone (Fig. 4a) . The antagonist alone (1 to 10 M) had no effect on NOS III mRNA expression (Fig. 4a) . Fig. 5a ). Also, NO production by EA.hy 926 cells was reduced after treatment of the cells with dexamethasone for 36 h (Fig. 5b) or with 10 M dihydrocortisol for 36 h (reduction to 72.6 Ϯ 4.3% of control, n ϭ 3, data not shown).
Dexamethasone Treatment Destabilized the NOS III mRNA and Inhibited the Activity of the NOS III Promoter. When transcription was blocked with 10 g͞ml actinomycin D added to the incubation medium of EA.hy 926 cells and RNA was prepared from these cells 6 to 48h later, NOS III mRNA levels were found to decline over time (Fig. 6a) . The approximate half-life of the mRNA was 48 h. Treatment of EA.hy 926 cells with dexamethasone (100 nM, 18 h) reduced the stability of the NOS III mRNA (Fig. 6a) . EA.hy 926 cells stably transfected with the plasmid pNOS III-Hu-3500-Luc-neo showed significant NOS III promoter activity. When the transfected cells were incubated for 18 h with 10-1,000 nM dexamethasone, promoter activity decreased to Ϸ70% of control (Fig. 6b) .
Effect of Dexamethasone on the Binding of Nuclear Extracts to
Transcription Factor-Binding DNA Motifs. The known sequence of the human NOS III promoter (GenBank accession no. AF032908) contains no bona fide glucocorticoid response element. Therefore, we tested the effect of dexamethasone on the binding activity of other transcription factors known to be important for the activity of the human NOS III promoter, namely Sp1 and GATA (27) (28) (29) . As shown in Fig. 7 , dexamethasone treatment of EA.hy 926 cells reduced the binding activities of nuclear extracts to an oligonucleotide containing the GATA site of the human NOS III promoter (positions Ϫ239 to Ϫ218) in a concentration-dependent fashion (n ϭ 4). The same results were obtained with an oligonucleotide containing a consensus GATA binding motif (n ϭ 5, data not shown). On the other hand, nuclear extracts from dexamethasone-treated endothelial cells showed unchanged binding activity to oligonucleotides containing the Sp1 element of the human NOS III promoter (positions Asterisks indicate significant differences from control animals ( ** , P Ͻ 0.01, Wilcoxon rank sum test) n.s., not significant. Ϫ109 to Ϫ91, n ϭ 4, data not shown) or a consensus Sp1-binding motif (n ϭ 4, data not shown).
Discussion
Because NOS III is a vasoprotective enzyme (8), changes in its expression and͞or activity may have important consequences for vascular homeostasis. The NO produced by NOS III actively decreases vascular resistance, as demonstrated with NOS III inhibitors and mice lacking the NOS III gene (2). Cushing's syndrome is associated with hypertension, and, also, synthetic glucocorticoids-when administered for prolonged periods of time-are known to increase blood pressure (11) . Although cortisol-induced hypertension is characterized by Na ϩ retention and volume expansion, studies with synthetic glucocorticoids or Na ϩ restriction suggest that the hypertension is, to a substantial degree, independent of Na ϩ and volume (11) . Also, in the current study, the blood pressure-elevating effects of dexamethasone are unlikely to be attributable to marked Na ϩ and water retention because no change in plasma or urine Na ϩ or K ϩ concentrations were noted. Evidence for separate mechanisms of glucocorticoid-and mineralocorticoid-induced hypertension comes from experiments with Wistar-Furth rats. This strain does not develop hypertension when treated with salt and mineralocorticoids. Wistar-Kyoto rats developed hypertension when treated with either deoxycorticosterone acetate͞NaCl or dexamethasone whereas Wistar-Furth rats developed hypertension only after dexamethasone treatment (30) .
Increase in cardiac output is not essential for the glucocorticoid-induced rise in blood pressure, but the precise role of increases in peripheral resistance as a primary mechanism has not been determined. Increased pressor responsiveness, particularly to catecholamines and angiotensin II, is a prominent feature, but its mechanism is poorly understood (10, 11) . In vitro studies have shown that the number of angiotensin II type 1 receptors of vascular smooth muscle cells is increased by glucocorticoids (11) . Also, a reduced activity of depressor systems, such as the kallikrein-kinin system, vasodilator prostaglandins and NO, has been discussed (11) .
In the current study, we have demonstrated that glucocorticoids lead to a substantial down-regulation of endothelial NOS mRNA and protein. This has been shown in vitro in three types of cultured endothelial cells from two species (Figs. 4 and 5 ) and in the aorta and some other rat tissues ex vivo (Fig. 2) . The down-regulation was prominent in the liver, which is a highly vascularized organ that contains a large number of endothelial cells. The finding that NOS III mRNA expression was not reduced in the heart may be explained by the fact that, in this organ, most of the NOS III is present in cardiomyocytes (31) , where its expression may be regulated differently from endothelial cells. The decreased protein expression of NOS III resulted in a reduced NO production, as demonstrated by a smaller stimulation of soluble guanylyl cyclase in RFL-6 cells in vitro (Fig. 5b) and lower serum levels of NO 2 Ϫ ͞NO 3 Ϫ in rats in vivo. This was paralleled by an increase in blood pressure. A similar increase in blood pressure was achieved with a moderate dose of the NOS inhibitor L-NAME, which produced a similar reduction in plasma NO 2 Ϫ ͞NO 3 Ϫ concentrations. The pathophysiological relevance of the dexamethasone effect also was demonstrated in vivo by intravital microscopy, in which resistance arterioles of dexamethasone-treated mice exhibited significantly attenuated vasorelaxation in response to the endothelium-dependent vasodilator acetylcholine but not to the endothelium-independent vasodilator SNAP (Fig. 3) .
The molecular mechanism of NOS III down-regulation by glucocorticoids seems to involve both mRNA destabilization (Fig. 6a) and reduced transcription of the NOS III gene (Fig. 6b) . The glucocorticoid receptor is a ligand-activated transcription factor, but the known 3.5 kilobases of the human NOS III promoter sequence lacks bona fide glucocorticoid response elements. Therefore, electrophoretic mobility shift assays were performed with oligonucleotides that contained consensus binding sequences for transcription factors Sp1 and GATA, whose importance for NOS III promoter activity have been demonstrated (27, 29) . In these experiments, dexamethasone reduced only the GATA binding activities of nuclear extracts of EA.hy 926 cells in a concentrationdependent fashion to almost undetectable levels (Fig. 7) . Sp1 binding remained unchanged. A mutation of the GATA binding site at position Ϫ230 of the human NOS III promoter has been shown to reduce promoter activity to Ϸ70% of control (27) . This corresponds well to the loss in promoter activity seen after dexamethasone treatment of endothelial cells (Fig. 6b) .
There is precedent for negative interaction of the activated glucocorticoid receptor with other transcription factors. For example, the inhibition of expression of the collagen gene by dexamethasone is brought about by a direct interaction of the glucocorticoid receptor with the AP-1 components c-JUN and c-FOS (32) . Touray et al. demonstrated that activated glucocorticoid receptors can form stable complexes with c-JUN or c-FOS in intact cells (33) . Also, for the inhibition by glucocorticoids of the IL-1␣-induced IL-8 expression in human T98G glioblastoma cells, the activated glucocorticoid receptor interferes with the binding of the essential transcription factor NF-B to its ciselement, thereby suppressing transcription of the IL-8 gene (34) . A similar mechanism is likely to be operative in the suppression of the inducible NOS II in human A549͞8 cells (22) . Thus, it seems conceivable that, in endothelial cells, the activated glucocorticoid receptor prevents the binding of transcription factor GATA to its cognate cis-element on the NOS III promoter.
In conclusion, we have demonstrated that dexamethasone and other glucocorticoids down-regulate the expression of the endothelial NOS III to 60-70% of control. This may contribute to the blood pressure increases seen during systemic administration of glucocorticoids. Fig. 7 . Electrophoretic mobility shift assay showing the effect of dexamethasone on the binding activity of nuclear extracts from EA.hy 926 cells to a doublestranded oligonucleotide containing the binding motif for transcription factor GATA of the human NOS III promoter (positions Ϫ239 to Ϫ218; 5Ј-GCTCCCACT-TATCAGCCTCAGT-3Ј). Nuclear extracts were prepared from control cells (Co) or from cells incubated for 18 h with dexamethasone (10 nM to 1 M) and were incubated with the radiolabeled oligonucleotide. Samples were analyzed on native polyacrylamide gels. Lane 1 shows radiolabeled oligonucleotide alone (oligo only). Lanes 5 and 6 (Cp1 and Cp2) show competition experiments with extracts from control (Co) cells and the addition of 100-fold excess of unlabeled oligonucleotide 5Ј-CACTTACAGAAAGTGATAACTCT-3Ј (containing a consensus GATA binding motif), or unlabeled oligonucleotide 5Ј-GCTCCCACTTATCAGCCT-CAGT-3Ј (containing the GATA site of the human NOS III promoter), respectively. The gel shown is representative of four gels yielding the same results.
